Together AI builds an agentic compiler to try and bring recursive self improvement capabilities to open source models.

abstract continue for new switch assert default goto* package synchronized boolean do if private this break double implements protected throw byte else import public throws case enum instanceof return ...

Startup Recursive has released Flint, a free, laptop-sized coding model built largely by its own AI research system, as an early test of AI that improves itself.

Astronauts on the International Space Station have a zero-g cup for their java. Credit: NASA Johnson Space Center Coffee linked to significant new side effect, says massive study 'The execution shall ...

As AI companies warn of the dangers of self-improving AI, a new report offers a rare look at how they’re working to make it a reality.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

“Recursive self-improvement” is the idea that artificial intelligence could learn to build and train itself, creating exponential new progress — and risk. Jeff Clune, a computer scientist and ...

How do you get from a chatbot that sometimes makes things up to a machine that humans might struggle to control? There are several steps in that argument, and plenty of uncertainty. But an idea known ...

Jacob Coxon talks to WIRED about the “mini Manhattan project” inside Anthropic, the problem with alignment, and why AI labs have just a few years left to make their systems safe. “The consensus is ...

Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth challenge its AI-driven drug discovery ambitions. RXRX's partnerships, notably with Genentech/Roche and ...

The up-to-$12 billion artificial intelligence (AI) drug discovery collaboration of Recursion, Roche, and its Genentech subsidiary marked a milestone Wednesday when plans were announced for Recursion ...

Roche Holding AG advanced the first project from its AI drug-discovery partnership with Recursion Pharmaceuticals, marking an early test of whether artificial intelligence can uncover new medicines.